Summary
The AI claims are largely about oral magnesium supplements and drug interactions (e.g., statins, warfarin, diuretics, beta-blockers, ACEi/ARBs, sotalol, myasthenia gravis) and general dosing/toxicity thresholds. The provided FDA label excerpts for magnesium sulfate in 5% dextrose injection only support use for seizure prevention/control in pre-eclampsia/eclampsia and warn about fetal harm with continuous administration beyond 5–7 days and magnesium intoxication in renal insufficiency. Most specific interaction, dosing, contraindication, and adverse-effect details made by the AI response are not supported by the supplied label excerpts and cannot be verified; multiple claims are therefore materially unsupported relative to the provided prescribing information.
Category Scores
Accurate Statements
Parenteral use in the presence of renal insufficiency may lead to magnesium intoxication.
Supported in provided excerpts: Section 5 WARNINGS: "Parenteral use in the presence of renal insufficiency may lead to magnesium intoxication."
Unsupported Statements
Magnesium supplements can interact with several heart drugs, potentially altering their effectiveness or causing side effects such as irregular heartbeat, low blood pressure, or toxicity.
Not supported in provided label excerpts; no listed interactions or claims about specific heart-drug classes in the supplied sections.
Magnesium may slightly reduce statin absorption if taken together.
Not supported in provided label excerpts.
Magnesium can enhance the effects of blood pressure medications such as calcium channel blockers, leading to excessive blood pressure drops or bradycardia.
Not supported in provided label excerpts.
Loop diuretics deplete magnesium.
Not supported in provided label excerpts.
Thiazide diuretics can raise magnesium levels.
Not supported in provided label excerpts.
High magnesium doses could amplify heart rate slowing in patients taking beta-blockers.
Not supported in provided label excerpts.
ACE inhibitors/ARBs may increase magnesium retention, risking hypermagnesemia in kidney-impaired patients.
Not supported in provided label excerpts.
Warfarin has minimal direct interaction with magnesium.
Not supported in provided label excerpts.
Magnesium glycinate forms might affect clotting indirectly and require INR monitoring.
Not supported in provided label excerpts (no INR/clotting guidance).
Magnesium deficiency worsens digoxin toxicity.
Not supported in provided label excerpts.
Supplementing magnesium can help with digoxin toxicity, but overdose risks arrhythmias.
Not supported in provided label excerpts.
Typical supplemental doses of magnesium (200–400 mg elemental magnesium daily) are often fine for most people.
Not supported in provided label excerpts; label excerpts discuss IV magnesium sulfate infusions and do not provide elemental daily oral supplement dosing.
Heart patients should start with a low magnesium dose (under 350 mg) and aim for food sources such as nuts, spinach, or bananas first.
Not supported in provided label excerpts.
Excess magnesium (over 5,000 mg) can cause diarrhea, nausea, or cardiac arrest.
Not supported in provided label excerpts; no mg threshold or those specific GI/cardiac arrest claims provided.
Low magnesium is common with diuretics or alcohol use.
Not supported in provided label excerpts.
Low magnesium raises risks of arrhythmias or worsened heart failure.
Not supported in provided label excerpts.
Symptoms of magnesium issues can include muscle cramps, fatigue, or palpitations.
Not supported in provided label excerpts (excerpts list intoxication-related signs such as hypotension, depressed reflexes, flaccid paralysis, respiratory paralysis).
Blood tests guide magnesium supplementation.
Not supported as a general supplementation/monitoring instruction in provided label excerpts; while the label excerpt mentions serum magnesium levels in clinical pharmacology, it does not endorse supplementation strategy/monitoring for supplements.
Magnesium should be avoided in people with kidney disease.
Not supported as a categorical contraindication in provided label excerpts; provided label says parenteral use in renal insufficiency may lead to magnesium intoxication, but only specific contraindication excerpt provided is toxemia of pregnancy during the two hours preceding delivery.
Magnesium should be avoided in people with myasthenia gravis.
Not supported in provided label excerpts.
Magnesium should be avoided without advice in people taking antibiotics or heart rhythm drugs such as sotalol.
Not supported in provided label excerpts.
Enteric-coated magnesium forms reduce stomach upset but slow absorption.
Not supported in provided label excerpts; formulation/route-specific GI tolerability and absorption claims not provided.
Contradictions
Low
AI Statement
Magnesium should be avoided in people with kidney disease.
Label Reference
Section 4 CONTRAINDICATIONS excerpt provided: "Intravenous magnesium should not be given to mothers with toxemia of pregnancy during the two hours preceding delivery." Section 5 WARNINGS excerpt provided addresses renal insufficiency as a risk for intoxication but does not provide a contraindication statement in the supplied text.
Low
AI Statement
Typical supplemental doses of magnesium (200–400 mg elemental magnesium daily) are often fine for most people.
Label Reference
Sections 2 DOSAGE AND ADMINISTRATION and 1 INDICATIONS AND USAGE excerpt provided: the label is for IV magnesium sulfate in 5% dextrose for pre-eclampsia/eclampsia seizure prevention/control and does not provide the stated oral elemental dosing regimen.
Important Omissions
Specific FDA-supported indication, route, and treatment context for magnesium sulfate in 5% dextrose injection (IV use only; prevention/control of seizures in pre-eclampsia/eclampsia).
Importance:
Moderate
Label contraindication timing for toxemia of pregnancy (IV magnesium should not be given during the two hours preceding delivery).
Importance:
Moderate
Label-specific warnings about fetal harm with continuous administration beyond 5–7 days and magnesium intoxication manifestations and effects relevant to parenteral use.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
The AI response makes numerous unsupported claims about drug interactions, dosing thresholds, contraindications (kidney disease, myasthenia gravis, sotalol/antibiotics), and symptom/monitoring guidance for magnesium supplements, none of which are substantiated by the provided label excerpts for magnesium sulfate in 5% dextrose injection. This creates a high risk of inaccurate patient guidance relative to the supplied prescribing information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims are not supported by the provided FDA label excerpts and appear to generalize magnesium supplement guidance and interactions unrelated to magnesium sulfate in 5% dextrose injection for pre-eclampsia/eclampsia seizures.
Suggested Improvement
Limit statements to what is explicitly supported in the provided label excerpts (indication for pre-eclampsia/eclampsia seizure prevention/control; IV use only; toxemia-of-pregnancy contraindication timing; fetal harm with continuous administration beyond 5–7 days; renal insufficiency risk for intoxication; listed adverse effects/toxicity manifestations). Remove or qualify all interaction, dosing, contraindication, monitoring, and formulation/route assertions that are not supported by the supplied labeling.